NATIONAL CANCER CENTER HOSPITAL EAST
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1962-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
26
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
- Conditions
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- Drug: LevofolinateRadiation: Radiation Therapy
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 26
- Registration Number
- NCT07018570
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
- Conditions
- Anaplastic Thyroid Cancer
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 51
- Registration Number
- NCT05696548
- Locations
- 🇯🇵
Aichi Cancer Center, Nagoya, Aichi, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵Hyogo Cancer Center, Akashi, Hyogo, Japan
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
- Conditions
- Salivary Gland Cancer
- Interventions
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 56
- Registration Number
- NCT05694819
- Locations
- 🇯🇵
Nagoya University Hospital, Nagoya, Aichi, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵Hokkaido University Hospital, Sapporo, Hokkaido, Japan
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer
- Conditions
- Locally Advanced Rectal Cancer
- Interventions
- Radiation: SCRTDrug: CAPOXDrug: CAPOXIRI
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 608
- Registration Number
- NCT05646511
- Locations
- 🇯🇵
Kyoto Prefectural University of Medicine, Kyoto, Japan
🇯🇵Osaka Metropolitan University Hospital, Osaka, Japan
🇯🇵National Cancer Center Hospital East, Chiba, Japan
Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy
- Conditions
- Gastroesophageal Junction AdenocarcinomaEsophageal AdenocarcinomaGastric Adenocarcinoma
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 30
- Registration Number
- NCT05394740
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
- Prev
- 1
- 2
- 3
- Next
News
Flatiron Health Triples Global Oncology Research Network, Expanding Real-World Data Access Across Three Countries
Flatiron Health's international oncology research network has tripled in size over the past year, now encompassing more than 30 partnerships across the UK, Germany, and Japan.
Lunit Presents 12 AI-Powered Studies at ASCO 2025, Demonstrating Enhanced Cancer Treatment Selection
Lunit will present 12 studies at ASCO 2025 showcasing AI-powered digital pathology solutions for precision oncology applications.
Lonsurf Shows Promising Survival Benefits for Stage 4 Colorectal Cancer Patients with Molecular Residual Disease
Phase 3 ALTAIR study reveals Lonsurf (trifluridine/tipiracil) significantly extended disease-free survival to 9.76 months versus 3.96 months with placebo in stage 4 colorectal cancer patients.